This invention relates generally to a single dose inhaler and insulin formation containers. The inhaler dispenses aerosolized pharmaceutical agents for local or systemic inhalation drug delivery to the lungs. The invention is particularly, but not exclusively, useful for delivery of preservative free doses of insulin for treating type I and/or type II diabetic patients.
Various types of inhalers exist for aerosolizing liquids. For example, U.S. Pat. No. 5,586,550, incorporated herein by reference, describes an inhaler which comprises a dispensing apparatus in which a membrane with tapered apertures is vibrated such that liquid in contact with a rear face of the membrane is dispensed from a front face of the membrane as an aerosol.
While effective at nebulizing liquids, such inhalers may not be particularly suited for certain applications, such as aerosolizing unit doses of insulin for pulmonary delivery.
Hence, the invention provides inhalers for delivering doses in a repeatable and predictable fashion. As described hereinafter, the inhalers of the invention may find particular use in aerosolizing liquid insulin for pulmonary delivery.
The invention provides various aerosolization systems, including containers for supplying liquid to inhalers, as well as methods for their use. In one exemplary embodiment, the invention provides an aerosolization system that comprises a squeezable container having a resilient container body. The container is configured to deliver a unit dosage of a liquid when squeezed a single time.
The system further includes an aerosolizer that comprises a housing defining a mouthpiece, and an aerosol generator disposed in the housing. The aerosol generator comprises a vibratable membrane having a front face and a rear face, and a vibratable element used to vibrate the membrane. Further, the housing includes an opening that is adapted to receive a unit dosage of the liquid from the container. The opening provides a liquid path to the rear face of the vibratable membrane.
In one aspect, the aerosolizer includes a hollow needle that is configured to pierce the squeezable container and to supply the liquid to the rear face of the vibratable membrane. Also, the squeezable container may comprise a blister containing a single unit dosage. For example, the blister may comprise a blow-fill-seal container that contains a preservative free solution. The blister may further comprise a squeezable body containing the solution, a twist off top and a tab adapted to display information about the solution.
In a further aspect, the single unit dosage has a concentration in the range from about 200 insulin units (“IU”)/ml to about 800 IU/ml.
In another embodiment, the container comprises a bottle containing of volume of the liquid. In one aspect, the bottle may include a metering valve that permits dispensing of a discrete droplet of the liquid each time the bottle is squeezed. In other cases, the size of the droplet may be controlled based at least in part on the diameter of the tip of the bottle and the viscosity of the liquid.
The invention further provides another aerosolization system that comprises a container in the form of an ampoule containing a capillary that holds a single unit dosage of a liquid. The system also includes an aerosolizer comprising a housing defining a mouthpiece, and an aerosol generator disposed in the housing. The aerosol generator comprises a vibratable membrane having a front face and a rear face, and a vibratable element used to vibrate the membrane. Also, the housing includes an opening that is adapted to receive a unit dosage of the liquid from the container. Further, the opening provides a liquid path to the rear face of the vibratable membrane.
In one particular aspect, the ampoule further comprises a snap-off top and a snap-off bottom. The capillary is sized such that surface tension in the capillary prevents leakage of the liquid after removal of the top but prior to removal of the bottom.
A further embodiment of the invention provides an aerosolization system having a container comprising a container body that holds a supply of liquid, and a plunger device that is movable to dispense a single unit dosage of a liquid from the container upon operation of the plunger device a set distance. An aerosolizer comprises a housing defining a mouthpiece, and an aerosol generator disposed in the housing. The aerosol generator comprises a vibratable membrane having a front face and a rear face, and a vibratable element used to vibrate the membrane. Further, the housing includes an opening that is adapted to receive a unit dosage of the liquid from the container. The opening provides a liquid path to the rear face of the vibratable membrane.
In one aspect, the container further includes a metering device that is rotated to control movement of the plunger in order to set a single unit dosage amount.
Certain aspects of the invention describe an aerosolizing apparatus comprising a housing defining a dispensing outlet, a vibratable membrane having a front face exposed at the outlet and a rear face for receiving a liquid to be dispensed, and a vibrating mechanism connected to the housing and operable to vibrate the membrane to dispense aerosol of the liquid through the membrane. A liquid delivery system is used to deliver a metered quantity of the liquid from to the rear face of the membrane. In this way, a metered quantity of liquid is dispensable at the outlet by operating the vibrating mechanism for an operating period sufficient to completely aerosolize the metered quantity of the rear face.
An advantage of such an apparatus is that it facilitates the dispensing of substantially all of the liquid coming into contact with the rear face of the membrane as a single dose, especially when the metered dose is relatively small in volume. By dispensing the entire dose, the membrane is essentially free of liquid from one dose to the next. In this way, it is thereby possible to avoid contact between liquid and ambient air during periods of non-use between successive uses. For pharmaceutical preparations this is particularly important since it may obviate the need for the use of preservatives in the liquid and avoids evaporative losses. For example, various preservative free insulin formulations that may be used include those described in copending U.S. application Ser. No. 13/004,662, entitled “Preservative Free Insulin Formulations and Systems and Methods for Aerosolizing” and filed on the same date as the present application, previously incorporated by reference.
The liquid supply system in one embodiment may comprise a deformable thin-wall blister which contains a pharmaceutical agent. The supply system further comprises a mechanical press configured to deform the thin-walled blister such that a single, preservative free unit dose is delivered. The press mechanism is provided with a dispensing station provided with a piercing needle operable to pierce the blister and release its content upon actuation.
In one aspect, the needle has two ends, with the first end protruding from the surface of the dispensing station and a second end extending to rear face of the aerosol generator. In use the blister is seated in the dispensing station and the press mechanism forces the blister toward the needle which pierces through the thin wall. In this way, the needle provides a conduit for moving the liquid from the blister to the rear face of the vibratable membrane. When the press mechanism is released the blister expands and returns to its natural position. This expansion creates a suction action which removes the liquid from the needle and prevents dry out and clogging.
In a further aspect, the blister has a bellows shaped geometry which can elastically expand and compress. The term elastically expand and compress includes when the blister is fully compressed the internal stresses are still within the elastic range of the material in use, thus, the blister can return to its natural position when the press mechanism is released. In one particular aspect, the pharmaceutical agent fills at least 80% the internal volume of the blister and more preferably more than 90% of the volume. This prevents movement of liquid which in some cases may cause aggregation of the composition.
Conveniently, the end of the needle may be positioned in close proximity to the rear face of the vibratable membrane. Further, the housing may define a duct communicating between an air inlet and an outlet port. The dispensing outlet is located in the duct intermediate the air inlet and the outlet port such that the front face of the membrane is exposed to air within the duct. The outlet port may be a mouthpiece for inhalation or an adapter for nasal use.
Such an arrangement is particularly useful in the administration of inhaled pharmaceutical liquid products where it is required that a fine aerosol of liquid be entrained in an inhaled air flow passing through the mouthpiece. One example of such a liquid is an insulin composition.
Referring now to
Each time the dispensing system is operated it delivers a metered quantity of the liquid from the unit dose blister 201 to the rear face 109 of the aerosol generator. Hence, for each use a metered quantity of aerosolized pharmaceutical agent is dispensed at the mouthpiece outlet 105 by operation of the aerosol generator.
The blister 201 contains a predetermined volume of an active pharmaceutical agent to be dispensed. In one embodiment the blister 201 contains about 80 to about 120 micro-liters of insulin. The lower limit is typically at least about 15 micro-liters and the upper limit is typically about 1,000 micro-liters to about 2,000 micro-liters. One particularly useful range is about 80 micro-liters to about 120 micro-liters in a concentration of about 100 insulin units/ml or greater, and more preferably between about 200-800 units/ml, and in some cases as high as 2,500 units/ml. Blister 201 is made of thin-walled deformable material. Due to sensitivity of insulin to mechanical agitation, the blister 201 is filled-up to nearly its entire volume. Specifically, more than 80% of the volume is filled with insulin.
Inhaler 100 further includes a dispensing station configured to dispense the content of the blister 201 to the aerosol generator 108. The dispensing station includes a swivel arm member 104 and a blister seat 107. The blister seat 107 has a concave shape which may radially match the convex shape of the blister 201. The blister seat 107 further includes a hypodermic needle 112 which establishes a fluid passage from the blister to the vibrating aerosol generator 108. The needle 112 has two sections. The first section 112A extends from the dispensing seat and protrudes outwardly perpendicularly to blister seat 107. The second end 112B extends inwardly toward the aerosol generator 108 and is positioned in closed proximity to rear side of the vibrating membrane of aerosol generator 108. Typically, second end 112B will be less than 5 mm and more preferably less than 2 mm from the vibrating membrane of the aerosol generator 108. The hypodermic needle 112 may be made of stainless steel alloy type 316 with a gage size ranging from 22 gage to 26 gage. The first section 112A has a sharp slanted piercing tip. In use, blister 201 is placed upon the concave seat 107 and then the swivel arm 104 is rotated counter clockwise in the direction of arrow 115.
Conveniently, the force upon the swivel arm 104 may be applied by a thumb against the curved portion of the arm 104. This action forces the blister toward the piercing tip of the needle 112A which subsequently pierces the blister 201 and squeezes its content via the needle 112 through the outlet of the needle 112B and onto the aerosol generator 108. When the swivel arm 104 is fully depressed, the entire dose is delivered to the vibrating membrane of the aerosol generator 108.
When the end-of-dose indicator light 120 is actuated following inhalation of the contents of blister 201, the empty blister may be removed and discarded. When the thumb pressure on the swivel arm 104 is release the blister expands to its original shape. Expansion creates a vacuum inside the blister 201 which draws back any adhered fluid from the needle back to the blister, thereby leaving the interior of the needle dry to prevent material dry-out and clogging. To further prevent possible bacterial contamination the internal and/or the external surfaces of the needle, needle 112 may be coated with silver, a silver based coating or the like.
One exemplary dispenser is the Aptar OSD dispenser, developed by Ing. Erich Pfeiffer GmbH. Such a container is constructed of a squeeze bottle that is squeeze to dispense a droplet. When released, the nozzle prevents microbiological contaminants from entering into the remaining liquid. This is accomplished through a tip seal (see, for example, tip seal 560 of
In use, nozzle 551 is aligned with the opening 501 such that the drop is dispensed to the slope 503 and flows through the opening 502 to the aerosol generator. Preferably, the angle of slope 503 is greater than about 30 degrees relative to the axis of the opening 502. The diameter of opening 501 is about 10 mm to about 15 mm and the diameter of opening 502 is at least about 5 mm. The pharmaceutical fluid in the preservative free dispenser 550 may be contained in a collapsible sack to prevent excessive agitation and which may damaged by mechanical sloshing. For example, proteins, such as insulin, may be sensitive to mechanical agitation. Use of a collapsible sack may limit undesirable agitation.
In another alternative embodiment, instead of using a container of the type described in
Blister 602 comprises a squeezable body 604 having a tab 606 and a twist off top 608. Body 604 is sized to hold a unit dosage of liquid, and tab 66 may include various types of identifying information, such as the lot number, date, and the like. Twist off top 608 provides a easy way to open blister 602 so that the liquid can be dispensed.
Referring also to
When ready to dispense the liquid into an inhaler, top end 706 is removed as illustrated in
Container 800 can be configured to be disposable or reusable. When reusable, reservoir 804 may comprise a cartridge that is inserted into the space defined by reservoir 804. Exemplary volume sizes may be about 1, 1.8 or 3 ml cartridges, which may be constructed of glass, LDPE or the like.
The invention has now been described in detail for purposes of clarity and understanding. However, it will be appreciated that certain changes and modifications may be practiced within the scope of the appended claims.
This application is a continuation of U.S. patent application Ser. No. 15/165,662, filed on May 26, 2016, which is a continuation of U.S. patent application Ser. No. 14/606,623, filed on Jan. 27, 2015, now U.S. Pat. No. 9,545,488, which is a continuation of U.S. patent application Ser. No. 14/039,254, filed on Sep. 27, 2013, now U.S. Pat. No. 9,004,061, which is a continuation of U.S. patent application Ser. No. 13/004,662, filed on Jan. 11, 2011, now U.S. Pat. No. 8,950,394, which claims priority from U.S. Provisional Application No. 61/335,769, filed on Jan. 12, 2010, which are incorporated by reference herein in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
1947310 | Sample et al. | Feb 1934 | A |
2463922 | Turner | Mar 1949 | A |
3789843 | Armstrong et al. | Feb 1974 | A |
3874380 | Baum | Apr 1975 | A |
4564129 | Urban et al. | Jan 1986 | A |
4694977 | Graf et al. | Sep 1987 | A |
5060642 | Gilman | Oct 1991 | A |
5164740 | Ivri | Nov 1992 | A |
5261601 | Ross et al. | Nov 1993 | A |
5333106 | Lanpher et al. | Jul 1994 | A |
5347998 | Hodson et al. | Sep 1994 | A |
5363842 | Mishelevich et al. | Nov 1994 | A |
5364838 | Rubsamen | Nov 1994 | A |
5385180 | Wittman et al. | Jan 1995 | A |
5479920 | Piper et al. | Jan 1996 | A |
5487378 | Robertson et al. | Jan 1996 | A |
5515842 | Ramseyer et al. | May 1996 | A |
5586550 | Ivri et al. | Dec 1996 | A |
5672581 | Rubsamen et al. | Sep 1997 | A |
5694919 | Rubsamen et al. | Dec 1997 | A |
5743250 | Gonda et al. | Apr 1998 | A |
5758637 | Ivri et al. | Jun 1998 | A |
5809997 | Wolf | Sep 1998 | A |
5884620 | Gonda et al. | Mar 1999 | A |
5915378 | Lloyd et al. | Jun 1999 | A |
5938117 | Ivri | Aug 1999 | A |
5941240 | Gonda et al. | Aug 1999 | A |
6014970 | Ivri et al. | Jan 2000 | A |
6062212 | Davison | May 2000 | A |
6085740 | Ivri et al. | Jul 2000 | A |
6085753 | Gonda et al. | Jul 2000 | A |
6098615 | Lloyd et al. | Aug 2000 | A |
6131567 | Gonda et al. | Oct 2000 | A |
6164498 | Faughey et al. | Dec 2000 | A |
6205999 | Ivri et al. | Mar 2001 | B1 |
6257454 | Ritsche | Jul 2001 | B1 |
6312665 | Modi | Nov 2001 | B1 |
6408854 | Gonda et al. | Jun 2002 | B1 |
6427682 | Klimowicz et al. | Aug 2002 | B1 |
6467476 | Ivri et al. | Oct 2002 | B1 |
6540153 | Ivri | Apr 2003 | B1 |
6540154 | Ivri et al. | Apr 2003 | B1 |
6629646 | Ivri | Oct 2003 | B1 |
6640804 | Ivri et al. | Nov 2003 | B2 |
6647987 | Gonda et al. | Nov 2003 | B2 |
6688304 | Gonda et al. | Feb 2004 | B2 |
6712762 | Lichter et al. | Mar 2004 | B1 |
6729327 | McFarland, Jr. | May 2004 | B2 |
6748946 | Rand et al. | Jun 2004 | B1 |
6755189 | Ivri et al. | Jun 2004 | B2 |
6790178 | Mault et al. | Sep 2004 | B1 |
6814071 | Klimowicz et al. | Nov 2004 | B2 |
6921020 | Ivri | Jul 2005 | B2 |
6926208 | Ivri | Aug 2005 | B2 |
6958691 | Anderson et al. | Oct 2005 | B1 |
6978941 | Litherland et al. | Dec 2005 | B2 |
7028686 | Gonda et al. | Apr 2006 | B2 |
7032590 | Loeffler et al. | Apr 2006 | B2 |
7040549 | Ivri et al. | May 2006 | B2 |
7066398 | Borland et al. | Jun 2006 | B2 |
7083112 | Ivri | Aug 2006 | B2 |
7100600 | Loeffler et al. | Sep 2006 | B2 |
7108197 | Ivri | Sep 2006 | B2 |
7117867 | Cox et al. | Oct 2006 | B2 |
7174888 | Ivri et al. | Feb 2007 | B2 |
7195011 | Loeffler et al. | May 2007 | B2 |
7219664 | Ruckdeschel et al. | May 2007 | B2 |
7448375 | Gonda et al. | Nov 2008 | B2 |
7451760 | Denyer et al. | Nov 2008 | B2 |
7600511 | Power et al. | Oct 2009 | B2 |
7600512 | Lee et al. | Oct 2009 | B2 |
7628339 | Ivri et al. | Dec 2009 | B2 |
7683029 | Hindle et al. | Mar 2010 | B2 |
7819115 | Sexton et al. | Oct 2010 | B2 |
7886783 | Rindy et al. | Feb 2011 | B2 |
8082918 | Jansen et al. | Dec 2011 | B2 |
8326964 | Chourey et al. | Dec 2012 | B1 |
8736227 | Chadbourne et al. | May 2014 | B2 |
8950394 | Patton et al. | Feb 2015 | B2 |
9004061 | Patton et al. | Apr 2015 | B2 |
9180261 | Patton et al. | Nov 2015 | B2 |
9545488 | Patton et al. | Jan 2017 | B2 |
10525214 | Patton et al. | Jan 2020 | B2 |
20010037805 | Gonda et al. | Nov 2001 | A1 |
20010039948 | Sexton et al. | Nov 2001 | A1 |
20020129813 | Litherland | Sep 2002 | A1 |
20030019493 | Narayan et al. | Jan 2003 | A1 |
20030041859 | Abrams et al. | Mar 2003 | A1 |
20030072740 | Milstein et al. | Apr 2003 | A1 |
20030101991 | Trueba | Jun 2003 | A1 |
20030150446 | Patel et al. | Aug 2003 | A1 |
20040100509 | Sommerer et al. | May 2004 | A1 |
20040134494 | Papania et al. | Jul 2004 | A1 |
20040154617 | Enk | Aug 2004 | A1 |
20040223917 | Hindle et al. | Nov 2004 | A1 |
20040256488 | Loeffler et al. | Dec 2004 | A1 |
20050011514 | Power et al. | Jan 2005 | A1 |
20050030953 | Vasudevan et al. | Feb 2005 | A1 |
20050133024 | Coifman | Jun 2005 | A1 |
20050166913 | Sexton et al. | Aug 2005 | A1 |
20050172958 | Singer et al. | Aug 2005 | A1 |
20050240084 | Morice et al. | Oct 2005 | A1 |
20060239930 | Lamche et al. | Oct 2006 | A1 |
20060261084 | Grey et al. | Nov 2006 | A1 |
20070074722 | Giroux et al. | Apr 2007 | A1 |
20070113841 | Fuchs | May 2007 | A1 |
20070163572 | Addington et al. | Jul 2007 | A1 |
20070209659 | Ivri et al. | Sep 2007 | A1 |
20080017188 | Pardonge et al. | Jan 2008 | A1 |
20080020794 | Garon et al. | Jan 2008 | A1 |
20080029083 | Masada et al. | Feb 2008 | A1 |
20080060641 | Smith et al. | Mar 2008 | A1 |
20080148193 | Moetteli | Jun 2008 | A1 |
20080184993 | Patel | Aug 2008 | A1 |
20080220747 | Ashkenazi et al. | Sep 2008 | A1 |
20080233053 | Gross et al. | Sep 2008 | A1 |
20080306794 | Cohen et al. | Dec 2008 | A1 |
20090025718 | Denyer | Jan 2009 | A1 |
20090095292 | Hamano et al. | Apr 2009 | A1 |
20090099065 | Madsen et al. | Apr 2009 | A1 |
20090140010 | Pruvot | Jun 2009 | A1 |
20090151718 | Hunter et al. | Jun 2009 | A1 |
20090156952 | Hunter et al. | Jun 2009 | A1 |
20090157037 | Iyer et al. | Jun 2009 | A1 |
20090194104 | Van Sickle | Aug 2009 | A1 |
20090241948 | Clancy | Oct 2009 | A1 |
20090301472 | Kim et al. | Dec 2009 | A1 |
20100075001 | Succar et al. | Mar 2010 | A1 |
20100094099 | Levy et al. | Apr 2010 | A1 |
20100153544 | Krassner et al. | Jun 2010 | A1 |
20100154793 | Kobayashi et al. | Jun 2010 | A1 |
20100180890 | Nobutani | Jul 2010 | A1 |
20100236545 | Kern | Sep 2010 | A1 |
20100250280 | Sutherland | Sep 2010 | A1 |
20100250697 | Hansen et al. | Sep 2010 | A1 |
20100319686 | Schennum | Dec 2010 | A1 |
20100326436 | Kaneko | Dec 2010 | A1 |
20110022350 | Chatterjee | Jan 2011 | A1 |
20110114089 | Andersen et al. | May 2011 | A1 |
20110125594 | Brown et al. | May 2011 | A1 |
20110168172 | Patton et al. | Jul 2011 | A1 |
20110225008 | Elkouh et al. | Sep 2011 | A1 |
20110246440 | Kocks et al. | Oct 2011 | A1 |
20110253139 | Guthrie et al. | Oct 2011 | A1 |
20120032901 | Kwon | Feb 2012 | A1 |
20120037154 | Gallem et al. | Feb 2012 | A1 |
20120069803 | Iwamura et al. | Mar 2012 | A1 |
20120116241 | Shieh | May 2012 | A1 |
20120144303 | Cricks et al. | Jun 2012 | A1 |
20120155987 | Watanabe | Jun 2012 | A1 |
20120285236 | Haartsen et al. | Nov 2012 | A1 |
20130155987 | Lan et al. | Jun 2013 | A1 |
20130318471 | Freyhult et al. | Nov 2013 | A1 |
20140010187 | Huang et al. | Jan 2014 | A1 |
20140362831 | Young | Dec 2014 | A1 |
20150092590 | Zhu et al. | Apr 2015 | A1 |
20150196721 | Patton et al. | Jul 2015 | A1 |
Number | Date | Country |
---|---|---|
1062091 | Jun 1992 | CN |
2406684 | Nov 2000 | CN |
1303309 | Jul 2001 | CN |
2461580 | Nov 2001 | CN |
101080249 | Nov 2007 | CN |
101300041 | Nov 2008 | CN |
101316660 | Dec 2008 | CN |
101495168 | Jul 2009 | CN |
111875 | Jun 1984 | EP |
311863 | Apr 1989 | EP |
2 835 435 | Aug 2003 | FR |
08502689 | Mar 1996 | JP |
2188041 | Aug 2002 | RU |
2336906 | Oct 2008 | RU |
2460677 | Sep 2012 | RU |
9822290 | May 1998 | WO |
03030829 | Apr 2003 | WO |
2004028608 | Apr 2004 | WO |
2005065756 | Jul 2005 | WO |
2006062449 | Jun 2006 | WO |
2006006963 | Jun 2006 | WO |
2007047948 | Apr 2007 | WO |
2008121610 | Oct 2008 | WO |
2009111612 | Sep 2009 | WO |
2010002421 | Jan 2010 | WO |
2010066714 | Jun 2010 | WO |
2010141803 | Dec 2010 | WO |
2011130183 | Oct 2011 | WO |
Entry |
---|
Liu, F-Y, “Pulmonary Delivery of Free Liposomal Insulin,” Pharmaceutical Research, Kluwer Academic Publishers, New York, NY, vol. 10, No. 2, Feb. 1, 1993, 5 pages. |
International Search Report and Written Opinion of PCT/US2011/020925 dated Mar. 14, 2011, 7 pages. |
International Search Report and Written Opinion of PCT/US2011/020926 dated Mar. 14, 2011, 11 pages. |
International Search Report and Written Opinion of PCT/US2013/034359 dated Jun. 28, 2013, 35 pages. |
European Search Report of EP 11733287 dated Jul. 12, 2013, 12 pages. |
EP Application No. 11733286.6 filed Jan. 12, 2011 received an Office Action dated Mar. 20, 2018, 4 pages. |
European Search Report for European Patent Application 11733286.6, dated Aug. 4, 2015, 5 pages. |
Australian Examination Report of related Australian application No. 2011205443 dated Mar. 13, 2015, 4 pages. |
Office Action of related Chinese Application No. 201180005839.9 dated Jun. 17, 2014, 16 pages. |
Office Action of related Chinese application No. 201180005839.9 dated March 3, 2015, 13 pages. |
Office Action of related Mexican application No. MX/a/2012/008010 dated Jul. 15, 2014, 5 pages. |
Office Action of related Mexican Patent Application No. MX/a/2012/008010 dated Nov. 12, 2014, 6 pages. |
Office Action of related Mexican Application No. MX/a/2012/008010 dated Feb. 12, 2015, 2 pages. |
U.S. Appl. No. 16/133,484 received a Final Office Action dated Jan. 22, 2021, 26 pages. |
Brazilian Application No. BR1120140258783 received an Office Action, dated Oct. 13, 2021, 5 pages. |
U.S. Appl. No. 14/133,484 received a Non-Final Office Action dated Nov. 9, 2021, 31 pages. |
Brazil Application No. BR1120120171771 received a Notice of Allowance dated Jul. 28, 2020, 1 page, no English Translation Available. |
U.S. Appl. No. 16/133,484 received a Non-Final Office Action dated Jul. 17, 2020, 19 pages. |
“On”, Oxfordictionaries.com, Oxford Dictionaries, 2016, Web, Jun. 21, 2016, 1 page. |
Spector et al., “Compliance of Patients with Asthma with an Experimental Aerosolized Medication: Implications for Controlled Clinical Trials”, Journal of Allergy and Clinical Immunology, vol. 77, No. 1, Jan. 1, 1986, pp. 65-70. |
BR1120140258783 received an office action dated Jan. 14, 2020, 7 pages. |
Chinese Application No. 201380031665.2, Notice of Decision to Grant dated Aug. 17, 2018, 6 pages (4 pages for the original document and 2 pages for the English translation). |
European Application No. 11733287.4, Office Action dated Aug. 9, 2016, 5 pages. |
European Application No. 13778058.1, Extended European Search Report dated Oct. 7, 2015, 5 pages. |
European Application No. 13778248.8, Extended European Search Report dated Oct. 26, 2015, 12 pages. |
European Application No. 13778248.8, Office Action dated Mar. 24, 2017, 5 pages. |
Indian Application No. 1921/MUMNP/2012, First Examination Report dated May 10, 2019, 7 pages. |
International Application No. PCT/US2011/020925, International Preliminary Report on Patentability dated Jul. 26, 2012, 6 pages. |
International Application No. PCT/US2011/020925, International Search Report and Written Opinion dated Mar. 14, 2011, 7 pages. |
International Application No. PCT/US2013/034354, International Preliminary Report on Patentability dated Oct. 30, 2014, 10 pages. |
International Application No. PCT/US2013/034354, International Search Report & Written Opinion dated Jun. 25, 2013, 12 pages. |
International Application No. PCT/US2013/034359, International Preliminary Report on Patentability dated Oct. 30, 2014, 7 pages. |
Russian Application No. 2012134422, Notice of Decision to Grant dated Feb. 17, 2015, 13 pages (8 pages for the original document and 5 pages for the English translation). |
U.S. Appl. No. 13/004,645, Final Office Action dated Sep. 20, 2013, 17 pages. |
U.S. Appl. No. 13/004,645, Final Office Action dated Apr. 29, 2014, 21 pages. |
U.S. Appl. No. 13/004,645, Final Office Action dated Mar. 10, 2015, 24 pages. |
U.S. Appl. No. 13/004,645, Non-Final Office Action dated Mar. 13, 2013, 15 pages. |
U.S. Appl. No. 13/004,645, Non-Final Office Action dated Nov. 25, 2013, 19 pages. |
U.S. Appl. No. 13/004,645, Notice of Allowance dated Jul. 8, 2015, 11 pages. |
U.S. Appl. No. 13/004,662, Final Office Action dated Aug. 22, 2014, 16 pages. |
U.S. Appl. No. 13/004,662, Final Office Action dated Jul. 18, 2013, 17 pages. |
U.S. Appl. No. 13/004,662, Non-Final Office Action dated Jan. 22, 2013, 10 pages. |
U.S. Appl. No. 13/004,662, Non-Final Office Action dated Apr. 18, 2014, 15 pages. |
U.S. Appl. No. 13/004,662, Non-Final Office Action dated Oct. 10, 2013, 15 pages. |
U.S. Appl. No. 13/004,662, Notice of Allowance dated Nov. 24, 2014, 13 pages. |
U.S. Appl. No. 13/830,511, Final Office Action dated Jul. 26, 2016, 26 pages. |
U.S. Appl. No. 13/830,511, Final Office Action dated Jan. 8, 2018, 38 pages. |
U.S. Appl. No. 13/830,511, Final Office Action dated Oct. 30, 2015, 45 pages. |
U.S. Appl. No. 13/830,511, Non-Final Office Action dated May 15, 2018, 26 pages. |
U.S. Appl. No. 13/830,511, Non-Final Office Action dated Apr. 5, 2017, 29 pages. |
U.S. Appl. No. 13/830,511, Non-Final Office Action dated Jun. 4, 2015, 36 pages. |
U.S. Appl. No. 13/830,511, Non-Final Office Action dated Mar. 11, 2016, 45 pages. |
U.S. Appl. No. 13/830,551, Final Office Action dated Jul. 31, 2015, 14 pages. |
U.S. Appl. No. 13/830,551, Final Office Action dated Sep. 22, 2016, 17 pages. |
U.S. Appl. No. 13/830,551, Final Office Action dated Sep. 10, 2018, 18 pages. |
U.S. Appl. No. 13/830,551, Final Office Action dated Oct. 3, 2017, 20 pages. |
U.S. Appl. No. 13/830,551, Non-Final Office Action dated Feb. 27, 2015, 12 pages. |
U.S. Appl. No. 13/830,551, Non-Final Office Action dated Apr. 11, 2016, 14 pages. |
U.S. Appl. No. 13/830,551, Non-Final Office Action dated May 26, 2017, 18 pages. |
U.S. Appl. No. 13/830,551, Non-Final Office Action dated Feb. 9, 2018, 23 pages. |
U.S. Appl. No. 13/840,588, Final Office Action dated Sep. 11, 2015, 30 pages. |
U.S. Appl. No. 13/840,588, Final Office Action dated Jun. 30, 2016, 32 pages. |
U.S. Appl. No. 13/840,588, Non-Final Office Action dated Feb. 24, 2016, 15 pages. |
U.S. Appl. No. 13/840,588, Non-Final Office Action dated Feb. 9, 2017, 25 pages. |
U.S. Appl. No. 13/840,588, Non-Final Office Action dated Mar. 16, 2015, 27 pages. |
U.S. Appl. No. 14/039,254, Advisory Action dated Sep. 10, 2014, 3 pages. |
U.S. Appl. No. 14/039,254, Corrected Notice of Allowability dated Mar. 18, 2015, 6 pages. |
U.S. Appl. No. 14/039,254, Final Office Action dated Jun. 11, 2014, 19 pages. |
U.S. Appl. No. 14/039,254, Non-Final Office Action dated Feb. 10, 2014, 17 pages. |
U.S. Appl. No. 14/039,254, Notice of Allowance dated Dec. 24, 2014, 14 pages. |
U.S. Appl. No. 14/606,623, Non-Final Office Action dated Mar. 8, 2016, 7 pages. |
U.S. Appl. No. 14/606,623, Notice of Allowability dated Dec. 14, 2016, 4 pages. |
U.S. Appl. No. 14/606,623, Notice of Allowance dated Apr. 18, 2016, 8 pages. |
U.S. Appl. No. 15/165,662, Advisory Action dated Jul. 10, 2017, 3 pages. |
U.S. Appl. No. 15/165,662, Advisory Action dated Jul. 24, 2018, 3 pages. |
U.S. Appl. No. 15/165,662, Advisory Action dated Jul. 29, 2019, 3 pages. |
U.S. Appl. No. 15/165,662, Final Office Action dated Jan. 30, 2017, 17 pages. |
U.S. Appl. No. 15/165,662, Final Office Action dated May 7, 2018, 19 pages. |
U.S. Appl. No. 15/165,662, Final Office Action dated May 10, 2019, 20 pages. |
U.S. Appl. No. 15/165,662, Non-Final Office Action dated Aug. 30, 2017, 17 pages. |
U.S. Appl. No. 15/165,662, Non-Final Office Action dated Aug. 8, 2016, 17 pages. |
U.S. Appl. No. 15/165,662, Non-Final Office Action dated Sep. 6, 2018, 19 pages. |
U.S. Appl. No. 15/165,662, Notice of Allowance dated Sep. 3, 2019, 8 pages. |
Brazil Application No. BR1120120171771 received an Office Action dated Feb. 27, 2020, 3 pages. No English Translation Available. |
Number | Date | Country | |
---|---|---|---|
20200078539 A1 | Mar 2020 | US |
Number | Date | Country | |
---|---|---|---|
61335769 | Jan 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15165662 | May 2016 | US |
Child | 16685382 | US | |
Parent | 14606623 | Jan 2015 | US |
Child | 15165662 | US | |
Parent | 14039254 | Sep 2013 | US |
Child | 14606623 | US | |
Parent | 13004662 | Jan 2011 | US |
Child | 14039254 | US |